查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1782007

減肥藥市場，按類型、按劑型、按應用、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Weight Loss Drugs Market, By Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年減肥藥市場規模價值 545.0322 億美元，2025 年至 2032 年的複合年成長率為 19.29%。

減肥藥市場-市場動態

提高對肥胖相關健康風險的認知

隨著公共衛生運動的興起、媒體關注度的提高以及持續的醫學研究逐漸揭示與肥胖相關的嚴重健康風險，例如第 2 型糖尿病、心臟病、某些癌症和呼吸問題，越來越多的人開始意識到控制體重的重要性。世界衛生組織 (WHO) 報告稱，自 1975 年以來，全球肥胖率幾乎成長了兩倍，2023 年超過 19 億成年人被認為超重，其中超過 6.5 億人被歸類為肥胖。這種日益成長的認知促使人們尋找有效的治療方案，包括減重藥物，以幫助減輕這些健康風險。因此，醫療保健提供者擴大建議在改變生活方式的同時進行藥物治療。對肥胖相關併發症的認知不斷提高，大大增加了全球對減肥藥物的需求，促使製藥公司開發更安全、更有效的方案來滿足這一迫切需求。

例如，

2024年1月，諾和諾德將其旗艦減肥藥物Wegovy（索馬魯肽）的供應範圍拓展至多個新的國際市場。此次擴張旨在滿足全球對有效肥胖治療藥物日益成長的需求，並鞏固諾和諾德在減重藥物領域的領導地位，幫助全球更多患者管理肥胖及其相關的健康風險。

減肥藥市場—關鍵洞察

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 19.29%

根據類型細分，處方藥預計在 2024 年佔據最大市場佔有率

根據劑型細分，注射劑是 2024 年的主要劑型

根據應用細分，食慾抑制是 2024 年的主要應用

根據配銷通路細分，零售藥局是2024年的主要分銷管道

按地區分類，北美是 2024 年的主要收入來源

減肥藥市場-細分分析：

全球減肥藥市場根據類型、劑型、應用、配銷通路和地區進行細分。

市場根據類型分為兩類：非處方藥 (OTC) 和處方藥。處方藥在減肥藥市場佔據主導地位，因為它們的有效性和安全性已得到證實，且需要醫療監督。這些藥物通常採用先進的配方，專門針對代謝途徑、食慾調節或脂肪吸收，使其在治療中度至重度肥胖方面更可靠。醫生更傾向於開立這些藥物，因為它們提供經臨床驗證的結果，並獲得了嚴格的監管批准。此外，肥胖相關健康併發症的日益增多，也促使醫師擴大推薦處方減肥藥。

根據應用，市場可分為三類：食慾抑制、脂肪阻斷及其他。食慾抑制領域佔據市場主導地位，食慾抑制劑透過作用於中樞神經系統來減少飢餓感和控制食慾，從而幫助人們減少卡路里攝取並促進持續減肥。這種直接控制食物攝取的方法使食慾抑制劑成為醫療保健提供者和患者的首選。此外，藥物配方的最新進展增強了其安全性和有效性，從而提高了患者的依從性和滿意度。隨著全球肥胖率持續上升，食慾抑制劑仍處於藥物體重管理的前沿，推動著市場的顯著成長和創新。

減肥藥市場—地理洞察

在 2024 年的預測期內，北美將主導全球減肥藥市場。

北美是減肥藥物市場的主導地區，憑藉其高肥胖率、強大的醫療基礎設施以及廣泛普及的先進藥物，佔據了最大的市場佔有率。尤其是美國，其成年人口中相當一部分被歸類為超重或肥胖，在該地區處於領先地位。此外，Wegovy（諾和諾德）和Zepbound（禮來）等減肥藥物的早期獲準和商業成功也推動了市場的成長。優惠的報銷政策、人們對肥胖相關健康風險的日益認知以及積極的政府支持，進一步鞏固了北美市場的主導地位。

預計在 2024 年的預測期內，亞太地區的減肥藥市場複合年成長率最高。

受快速城市化、久坐不動的生活方式和飲食習慣變化等因素驅動，亞太地區正成為成長最快的市場，肥胖率也隨之飆升。中國、印度和韓國等國正經歷糖尿病和心血管疾病等肥胖相關疾病的急劇上升。此外，可支配收入的增加、醫療保健服務可近性的改善以及減肥藥物治療的日益普及，也加速了市場需求。此外，不斷擴展的醫療保健計劃以及政府支持的旨在預防肥胖的公共衛生項目，也支持了亞太地區市場的快速擴張。

減肥藥市場-競爭格局：

減重藥物市場競爭激烈，發展迅速，這得益於製藥巨頭、新興生物技術公司以及肥胖症治療領域不斷成長的研發投入。諾和諾德、禮來、輝瑞、強生和葛蘭素史克等領導企業處於領先地位，透過創新、臨床試驗改進和全球市場擴張來競爭。

諾和諾德憑藉其暢銷藥物Wegovy（索馬魯肽）佔據主導地位，該藥物已展現出卓越的臨床療效，並在全球範圍內需求旺盛。禮來憑藉Zepbound（替澤帕肽）迅速成為其強大的競爭對手，為第2型糖尿病和減肥提供雙重優勢。為了滿足日益成長的需求，兩家公司都在大力投資產能並進入新市場。為了滲透或提升其在這個快速擴張的市場中的地位，輝瑞和葛蘭素史克正專注於產品線研發和策略合作。規模較小的生技公司也以客製化的肥胖症治療方案和創新的治療手段嶄露頭角。

市場在功效、安全性、給藥便利性和長期療效等方面的競爭日益激烈，各公司也積極尋求合作、授權交易和收購，以擴大業務範圍。隨著全球肥胖率持續攀升，減肥藥市場的競爭預計將持續激烈，從而促進持續的創新和商業活動。

最新動態：

2025年6月，禮來公司宣布與亞馬遜藥局達成策略合作，將其減肥藥Zepbound（tirzepatide）直接分銷給消費者。此舉旨在改善患者的可及性和便利性，同時擴大禮來公司在肥胖治療領域的數位健康影響力。在體重管理療法需求不斷成長的背景下，此次合作有助於該藥物的更廣泛應用。

2025年4月，諾和諾德收購了以口服給藥系統聞名的Emisphere Technologies公司。此次收購旨在改善Wegovy有效成分索馬魯肽的口服製劑，提高患者的依從性和可及性。此舉增強了諾和諾德的創新產品線，並支持其在注射和口服減肥療法領域保持領先地位的策略。

2025年1月，強生與美國生技公司達成合作開發協議，旨在研發用於肥胖管理的雙效代謝調節劑。此次合作致力於開發能更安全、長期有效減肥的下一代藥物。此舉體現了強生在應對全球肥胖和代謝紊亂領域的全新戰略興趣。

2024年10月，葛蘭素史克公司（GSK）啟動了一項針對中樞神經系統路徑的新型食慾抑制劑的第二期臨床試驗。這項創新是GSK透過首創療法拓展其代謝健康產品組合的更廣泛目標的一部分。本公司旨在開發高效能、患者依從性更高且副作用最小的療法。

目錄

第1章：減肥藥市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 減肥藥市場片段（按類型）
    • 減肥藥市場（按劑型）摘要
    • 減肥藥市場片段（按應用）
    • 減肥藥市場按配銷通路細分
    • 各國減肥藥市場概況
    • 減肥藥市場（按地區）
  • 競爭洞察

第3章：減肥藥主要市場趨勢

  • 減肥藥市場促進因素
    • 市場促進因素的影響分析
  • 減肥藥市場限制
    • 市場限制的影響分析
  • 減肥藥市場機遇
  • 減肥藥市場未來趨勢

第4章：減肥藥物產業研究

  • PESTEL分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：減肥藥市場：地緣政治緊張升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：減肥藥市場格局

  • 2024年減肥藥市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：減肥藥市場－依類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 非處方藥（OTC）
    • 處方藥

第8章：減肥藥市場－按劑型

  • 概述
    • 按劑型分類的細分市場佔有率分析
    • 膠囊
    • 注射
    • 液體
    • 平板電腦

第9章：減肥藥市場－依應用

  • 概述
    • 按應用細分市場佔有率分析
    • 抑制食慾
    • 脂肪阻斷
    • 其他

第10章：減肥藥市場－依配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 網路藥局
    • 醫院藥房
    • 零售藥局

第 11 章：減肥藥市場 - 按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美減肥藥主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按類型）
    • 北美市場規模及預測（按劑型）
    • 北美市場規模和預測（按應用）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲減肥藥主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模及預測（按劑型）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區減肥藥主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（按類型）
    • 亞太地區市場規模及預測（依劑型分類）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲減肥藥主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按類型）
    • 拉丁美洲市場規模及預測（以劑型分類）
    • 拉丁美洲市場規模及預測（按應用）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲減肥藥主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模和預測（按類型）
    • MEA 市場規模及預測（以劑型）
    • MEA 市場規模及預測（按應用）
    • MEA 市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：減肥藥物產業主要供應商分析

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Eli Lilly and Company
    • Amgen Inc.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • GlaxoSmithKline plc
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • Sanofi SA
    • Structure Therapeutics Inc.
    • Takeda Pharmaceutical Company Limited
    • VIVUS, Inc.
    • Zafgen, Inc.
    • Eisai Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5439

REPORT HIGHLIGHT

Weight Loss Drugs Market size was valued at US$ 54,503.22 Million in 2024, expanding at a CAGR of 19.29% from 2025 to 2032.

The Weight Loss Drugs Market is the global industry that develops, makes, and sells pharmaceutical products to help people lose weight. These drugs operate in different ways, like suppressing appetite, blocking fat absorption, or boosting metabolism to manage obesity and overweight issues. The market includes prescription medications, over-the-counter products, and new therapies aimed at tackling the rising rates of obesity-related health problems around the world. The market is growing due to increased awareness of the health risks associated with obesity, more sedentary lifestyles, and a higher demand for effective and safe weight management solutions.

Weight Loss Drugs Market- Market Dynamics

Rising awareness about health risks associated with obesity

With the rise of public health campaigns, increased media attention, and ongoing medical research shining a light on the serious health risks associated with obesity like type 2 diabetes, heart disease, certain cancers, and breathing issues more people are starting to realize just how important it is to manage their weight. The World Health Organization (WHO) reports that since 1975, the global rate of obesity has nearly tripled, with over 1.9 billion adults considered overweight in 2023, and more than 650 million of those classified as obese. This growing awareness is pushing individuals to look for effective treatment options, including weight loss medications, to help mitigate these health risks. Consequently, healthcare providers are increasingly suggesting pharmacological treatments alongside lifestyle changes. This growing consciousness about obesity related complications is significantly boosting the demand for weight loss drugs worldwide, prompting pharmaceutical companies to create safer and more effective options to address this pressing need.

For Instance,

In January 2024, Novo Nordisk expanded the availability of its flagship weight loss drug, Wegovy (semaglutide), to multiple new international markets. This expansion addresses the rising global demand for effective obesity treatments and reinforces Novo Nordisk's leadership in the weight loss drugs sector, aiming to help more patients manage obesity and related health risks worldwide.

Weight Loss Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.29% over the forecast period (2025-2032)

Based on type segmentation, prescription drugs were predicted to show maximum market share in the year 2024

Based on dosage form segmentation, injections was the leading dosage form in 2024

Based on application segmentation, appetite suppression was the leading application in 2024

Based on distribution channel segmentation, retail pharmacy was the leading distribution channels in 2024

On the basis of region, North America was the leading revenue generator in 2024

Weight Loss Drugs Market- Segmentation Analysis:

The global weight loss drugs market is segmented on the basis of type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on type: Over-the-counter drugs (OTC) and prescription drugs. The Prescription Drugs segment dominates the Weight Loss Drugs Market due to their proven effectiveness and safety profile, which require medical supervision. These drugs often involve advanced formulations that specifically target metabolic pathways, appetite regulation, or fat absorption, making them more reliable for treating moderate to severe obesity. Physicians prefer prescribing these medications because they provide clinically validated results and are supported by rigorous regulatory approvals. Additionally, the growing prevalence of obesity-related health complications is driving increased physician recommendation of prescription weight loss drugs.

The market is divided into three categories based on application: appetite suppression and fat blocking and others. The appetite suppression sector dominates the market and Appetite suppressants work by targeting the central nervous system to reduce feelings of hunger and control cravings, which helps individuals consume fewer calories and promotes sustained weight loss. This direct approach to managing food intake makes appetite suppressants a preferred choice for both healthcare providers and patients. Moreover, recent advancements in drug formulations have enhanced their safety profiles and effectiveness, increasing patient adherence and satisfaction. With obesity rates continuing to rise globally, appetite suppressants remain at the forefront of pharmacological weight management, driving significant market growth and innovation.

Weight Loss Drugs Market- Geographical Insights

North America dominates the global weight loss drugs market during the forecast period in 2024.

North America is dominating region in the weight loss drugs market, accounting for the largest market share due to its high prevalence of obesity, strong healthcare infrastructure, and widespread access to advanced medications. The United States, in particular, leads the region with a significant portion of the adult population classified as overweight or obese. Additionally, the early approval and commercial success of weight loss drugs such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) have boosted market growth. Favourable reimbursement policies, growing awareness about obesity-related health risks, and active government support further contribute to North America's market dominance.

Asia Pacific is estimated to register the highest CAGR in the weight loss drugs market during the forecast period in 2024.

Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, sedentary lifestyles, and dietary changes leading to a surge in obesity rates. Countries like China, India, and South Korea are experiencing a sharp rise in obesity-related diseases such as diabetes and cardiovascular disorders. Alongside this, increasing disposable incomes, improved access to healthcare, and growing acceptance of pharmaceutical treatments for weight loss are accelerating demand. Moreover, expanding healthcare initiatives and government-backed public health programs aimed at obesity prevention are supporting the market's rapid expansion across Asia-Pacific.

Weight Loss Drugs Market- Competitive Landscape:

The weight loss drugs market is highly competitive and rapidly evolving, driven by a mix of pharmaceutical giants, emerging biotech firms, and growing R&D investments in obesity treatment. Leading players such as Novo Nordisk, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline are at the forefront, competing through innovation, clinical trial advancements, and global market expansion.

With its popular medication Wegovy (semaglutide), which has demonstrated excellent clinical outcomes and great demand worldwide, Novo Nordisk presently holds a dominant market share. With Zepbound (tirzepatide), Eli Lilly has swiftly become a formidable competitor, providing dual-action advantages for type 2 diabetes and weight loss. To keep up with the increasing demand, both businesses are making significant investments in manufacturing capacity and entering new markets. To penetrate or improve their positions in this rapidly expanding market, Pfizer and GSK are concentrating on pipeline research and strategic partnerships. Smaller biotech businesses are also making an appearance with customized obesity treatments and innovative methods of action.

The market is witnessing increased competition in terms of efficacy, safety profiles, dosing convenience, and long-term outcomes, with companies also pursuing partnerships, licensing deals, and acquisitions to expand their reach. As obesity rates continue to climb globally, the competitive intensity in the weight loss drugs market is expected to remain strong, fostering ongoing innovation and commercial activity.

Recent Developments:

In June 2025, Eli Lilly announced a strategic collaboration with Amazon Pharmacy to distribute its weight loss drug Zepbound (tirzepatide) directly to consumers. The move aims to improve patient access and convenience, while expanding Eli Lilly's digital health footprint in the obesity treatment space. This partnership supports broader adoption amid rising demand for weight management therapies.

In April 2025, Novo Nordisk acquired Emisphere Technologies, a company known for oral drug delivery systems. This acquisition is intended to improve oral formulations of semaglutide, the active ingredient in Wegovy, enhancing patient compliance and accessibility. It strengthens Novo Nordisk's innovation pipeline and supports its strategy to lead in both injectable and oral weight loss therapies.

In January 2025, Johnson & Johnson entered into a co-development partnership with a U.S.-based biotech firm to create dual-acting metabolic modulators for obesity management. The collaboration focuses on developing next-generation drugs that offer safer, long-term weight loss. This move reflects J&J's renewed strategic interest in addressing global obesity and metabolic disorders.

In October 2024, GlaxoSmithKline (GSK) launched Phase 2 clinical trials for a novel appetite suppressant targeting central nervous system pathways. This innovation is part of GSK's broader goal to expand its metabolic health portfolio with first-in-class treatments. The company aims to develop therapies that offer high efficacy with improved patient compliance and minimal side effects.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL WEIGHT LOSS DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd (Roche Holding AG)
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Structure Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS, Inc.
  • Zafgen, Inc.
  • Eisai Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Over-the-counter drugs (OTC)
  • Prescription Drugs

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Injections
  • Liquids
  • Tablets

GLOBAL WEIGHT LOSS DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Appetite Suppression
  • Fat Blocking
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

GLOBAL WEIGHT LOSS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Weight Loss Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Weight Loss Drugs Market Snippet by Type
    • 2.1.2. Weight Loss Drugs Market Snippet by Dosage Form
    • 2.1.3. Weight Loss Drugs Market Snippet by Application
    • 2.1.4. Weight Loss Drugs Market Snippet by Distribution Channel
    • 2.1.5. Weight Loss Drugs Market Snippet by Country
    • 2.1.6. Weight Loss Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Weight Loss Drugs Key Market Trends

  • 3.1. Weight Loss Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Weight Loss Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Weight Loss Drugs Market Opportunities
  • 3.4. Weight Loss Drugs Market Future Trends

4. Weight Loss Drugs Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Weight Loss Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Weight Loss Drugs Market Landscape

  • 6.1. Weight Loss Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Weight Loss Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Over-the-counter drugs (OTC)
    • 7.1.3. Prescription Drugs

8. Weight Loss Drugs Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Capsules
    • 8.1.3. Injections
    • 8.1.4. Liquids
    • 8.1.5. Tablets

9. Weight Loss Drugs Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Appetite Suppression
    • 9.1.3. Fat Blocking
    • 9.1.4. Others

10. Weight Loss Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Online Pharmacy
    • 10.1.3. Hospital Pharmacy
    • 10.1.4. Retail Pharmacy

11. Weight Loss Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Weight Loss Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Weight Loss Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Weight Loss Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Weight Loss Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Weight Loss Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Weight Loss Drugs Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Eli Lilly and Company
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca
    • 12.2.4. F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • 12.2.5. GlaxoSmithKline plc
    • 12.2.6. Ionis Pharmaceuticals, Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Merck & Co., Inc.
    • 12.2.9. Novartis AG
    • 12.2.10. Teva Pharmaceutical Industries Ltd.
    • 12.2.11. Pfizer Inc.
    • 12.2.12. Rhythm Pharmaceuticals, Inc.
    • 12.2.13. Sanofi S.A.
    • 12.2.14. Structure Therapeutics Inc.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. VIVUS, Inc.
    • 12.2.17. Zafgen, Inc.
    • 12.2.18. Eisai Co., Ltd.
    • 12.2.19. Boehringer Ingelheim International GmbH
    • 12.2.20. Currax Pharmaceuticals LLC
    • 12.2.21. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us